Vogenx is a clinical-stage biopharmaceutical company developing oral therapies for metabolic diseases related to blood glucose dysregulation. The lead candidate, mizagliflozin, is an oral small molecule that inhibits SGLT1 in the small intestine. By blocking this transporter, the drug reduces and delays dietary glucose absorption to blunt insulin and GIP responses after eating. Mizagliflozin acts locally in the gut and is minimally absorbed into the bloodstream. Vogenx primarily targets post-bariatric hypoglycemia (PBH), a condition where patients experience dangerous blood sugar crashes after weight-loss surgery. There are currently no FDA-approved treatments for PBH. The company has completed Phase 2 studies for this indication and plans to begin a Phase 2b study in 2026. Vogenx is also developing mizagliflozin for gastroparesis and GIP-dependent Cushing’s Syndrome, with further clinical studies planned for 2027. As a pre-revenue company, Vogenx funds operations through equity and debt financing. The company licensed exclusive worldwide rights to mizagliflozin, excluding Japan, Korea, and Taiwan, from Kissei Pharmaceutical in exchange for milestone and royalty payments. Vogenx operates with an asset-light model, outsourcing manufacturing and clinical operations to third parties. Its strategy focuses on advancing its lead candidate through clinical trials to reach regulatory approval or potential partnerships.